In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuros Medical Inc.

www.neurosmedical.com

Latest From Neuros Medical Inc.

Market Intel: Peripheral Nerve Stim Players Edge Out Innovative Paths

While demand for spinal cord stimulation (SCS) devices used in pain management continues to expand at double-digit rates, a small but growing number of highly innovative companies that develop stimulators to specifically target peripheral nerve pain is creating excitement among pain doctors looking for better options to treat an intractable population that's seen little success with standard therapy. With millions of people worldwide suffering from low back pain, severe headaches and migraines, neck pain and other chronic pain, the demand for safe, effective, percutaneously-placed devices remains high. In this article, we'll highlight emerging companies working on PNS devices and provide insights from pain physicians on the pros and cons of these devices.

Neurology Commercial

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics

SPR Therapeutics: Peripheral Nerve Stimulation To Treat Pain

The Smartpatch from SPR Therapeutics LLC stimulates the peripheral nerves that carry the pain signal to the central nervous system. The minimally invasive and reversible neurostimulation system can remain implanted for up to 60 days, offering therapy to patients in acute as well as chronic pain.

Medical Device Innovation

SPR Therapeutics LLC

The Smartpatch from SPR Therapeutics LLC stimulates the peripheral nerves that carry the pain signal to the central nervous system. The minimally invasive and reversible neurostimulation system can remain implanted for up to 60 days, offering therapy to patients in acute as well as chronic pain.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neuros Medical Inc.
  • Senior Management
  • Jon Snyder, Pres. & CEO
    Bob W Centa, CFO
    Zi-Ping Fang, PhD, CSO
    Jan Dugas, VP, Clinical & Reg. Affairs
  • Contact Info
  • Neuros Medical Inc.
    Phone: (440) 951-2565
    35010 Chardon Rd.
    Ste. 210
    Willoughby Hills, OH 44094
    USA
UsernamePublicRestriction

Register